SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	₩1,785.00	+2.59%	79,328
09/26/09	₩1,740.00	-2.19%	57,077
08/26/08	₩1,779.00	-0.28%	1,32,569
07/26/07	₩1,784.00	+3.66%	26,685
06/26/06	₩1,721.00	+1.29%	20,304

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
1,785.00 ^KRW	+2.59%		+5.06%	-22.39%

15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	6.07TCr 4.04Cr 3.54Cr 3.26Cr 3.01Cr 5.72Cr 385.64Cr 5.81Cr 39Cr 15Cr 189.98Cr 15Cr 15Cr 653.11Cr	P/E 2024	-16x	P/E 2025	-19.2x
Enterprise Value	8.32TCr 5.54Cr 4.85Cr 4.47Cr 4.13Cr 7.84Cr 528.76Cr 7.97Cr 53Cr 21Cr 260.48Cr 21Cr 20Cr 895.49Cr	EV / Sales 2024	13.3x	EV / Sales 2025	4.57x
Free-Float	45.72%	Yield 2024 *	-	Yield 2025	-

15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/12	SCL Science Inc. agreed to acquire Bio-logistics business in Honam region of Seoul Clinical Laboratories for KRW 4.3 billion.	CI
14/11	SCL Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11/25/11	Scl Science to acquire 1.6 billion won worth of shares and majority stake in Pentamedix Co Ltd	RE
11/25/11	SCL Science Inc. agreed to acquire 60.31% stake in PentaMedix Co., Ltd. for KRW 1.6 billion.	CI
14/25/14	Scl Science wins 530 million won order	RE
14/25/14	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/25/28	SCL Science Inc. agreed to acquire Bio-logistics business in Yeongnam region of Seoul Clinical Laboratories from Seoul Clinical Laboratories for KRW 5.0 billion.	CI
15/25/15	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/25/31	SCL Science Inc. completed the acquisition of SCL Healthcare Co., Ltd.	CI
20/25/20	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	SCL Science Inc. announced that it has received KRW 14 billion in funding from a group of investors	CI

1 day	+2.59%
1 week	+5.06%
Current month	+6.25%
1 month	+0.28%
3 months	-19.59%
6 months	-20.49%
Current year	-22.39%

SCL Science Inc. Share Price

Stocks

A246960

KR7246960009

Pharmaceuticals

Valuation: SCL Science Inc.

Chart: SCL Science Inc.

Latest news : SCL Science Inc.

Quotes and Performance

Course Extremes

Managers and Directors: SCL Science Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,682	1,946
1 month	1,504	1,946
Current year	1,504	2,680
1 year	1,504	3,490
3 years	1,504	5,110
5 years	1,504	5,225
10 years	1,300	6,950

Manager	Title	Age	Since
Kyung-Yul Lee CEO	Chief Executive Officer	-	28/12/2022
Se-Yeon Baek CEO	Chief Executive Officer	59	30/09/2024
Dae-Young Kim AUD	Comptroller/Controller/Auditor	63	28/12/2022

Director	Title	Age	Since
Se-Yeon Baek BRD	Director/Board Member	59	30/09/2024
Kyung-Yul Lee BRD	Director/Board Member	-	28/12/2022
Jeong-Gyun Choi BRD	Director/Board Member	59	30/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/25/11	Choon-sik Yang	Free		13,650	0.0402%
11/25/11	Sang-cheol Kim	Free		12,582	0.0371%
11/25/11	Kyung-Yul Lee	Free	Chief Executive Officer	26,658	0.0786%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCL SCIENCE INC.	+2.59%	+5.06%	-44.13%	-16.00%	4.04Cr
REGENERON PHARMACEUTICALS, INC.	-0.51%	+1.57%	+18.72%	-5.52%	6.76TCr
UCB	-5.16%	-8.63%	+37.37%	+202.27%	5.16TCr
SAMSUNG BIOLOGICS CO.,LTD.	+5.28%	+39.50%	+39.50%	+39.50%	4.3TCr
CSL LIMITED	-2.10%	+0.89%	-49.30%	-53.47%	4.09TCr
BIOGEN INC.	+0.12%	-7.85%	+47.16%	-29.27%	2.94TCr
MODERNA, INC.	-10.83%	-14.41%	+99.15%	-44.54%	2.71TCr
INCYTE CORPORATION	-1.53%	-0.13%	+65.92%	+88.58%	2.33TCr
INNOVENT BIOLOGICS, INC.	+3.88%	+2.16%	+11.78%	+201.51%	1.99TCr
SWEDISH ORPHAN BIOVITRUM AB	-1.59%	-1.63%	+61.04%	+130.75%	1.69TCr
Average	-0.98%	-2.35%	+28.72%	+51.38%	3.2TCr
Weighted average by Cap.	-1.36%	-2.83%	+30.48%	+49.37%

	2024	2025
Net sales	473.71Cr 31.55L 27.59L 25.45L 23.51L 44.61L 30Cr 45.36L 3.04Cr 1.19Cr 15Cr 1.18Cr 1.16Cr 51Cr	2.2TCr 1.47Cr 1.28Cr 1.18Cr 1.09Cr 2.07Cr 139.8Cr 2.11Cr 14Cr 5.55Cr 69Cr 5.5Cr 5.38Cr 236.76Cr
Net income	-373.01Cr -24.84L -21.73L -20.04L -18.51L -35.12L -24Cr -35.71L -2.39Cr -94.04L -12Cr -93.27L -91.24L -40Cr	-393.43Cr -26.2L -22.92L -21.14L -19.52L -37.05L -25Cr -37.67L -2.53Cr -99.19L -12Cr -98.38L -96.24L -42Cr
Net Debt	314.54Cr 20.95L 18.32L 16.9L 15.61L 29.62L 20Cr 30.12L 2.02Cr 79.3L 9.84Cr 78.65L 76.94L 34Cr	2.25TCr 1.5Cr 1.31Cr 1.21Cr 1.12Cr 2.12Cr 143.12Cr 2.16Cr 14Cr 5.68Cr 71Cr 5.63Cr 5.51Cr 242.38Cr